DE2025810C3 - Verfahren zur Isolierung doppelstrangiger Ribonucleinsäure und diese Verbindung enthaltendes Arzneipräparat - Google Patents
Verfahren zur Isolierung doppelstrangiger Ribonucleinsäure und diese Verbindung enthaltendes ArzneipräparatInfo
- Publication number
- DE2025810C3 DE2025810C3 DE2025810A DE2025810A DE2025810C3 DE 2025810 C3 DE2025810 C3 DE 2025810C3 DE 2025810 A DE2025810 A DE 2025810A DE 2025810 A DE2025810 A DE 2025810A DE 2025810 C3 DE2025810 C3 DE 2025810C3
- Authority
- DE
- Germany
- Prior art keywords
- double
- rna
- ribonucleic acid
- isolation
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229920002477 rna polymer Polymers 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 5
- 238000002955 isolation Methods 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 title 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 102000014150 Interferons Human genes 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 9
- 229940079322 interferon Drugs 0.000 claims description 8
- 240000000599 Lentinula edodes Species 0.000 claims description 6
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 description 20
- 230000009385 viral infection Effects 0.000 description 17
- 239000000872 buffer Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 208000036142 Viral infection Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- WZIMSXIXZTUBSO-UHFFFAOYSA-N 2-[[bis(carboxymethyl)amino]methyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CN(CC(O)=O)CC(O)=O WZIMSXIXZTUBSO-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000725681 Swine influenza virus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- FLJPGEWQYJVDPF-UHFFFAOYSA-L caesium sulfate Chemical compound [Cs+].[Cs+].[O-]S([O-])(=O)=O FLJPGEWQYJVDPF-UHFFFAOYSA-L 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 241000221566 Ustilago Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4040469 | 1969-05-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2025810A1 DE2025810A1 (de) | 1970-12-17 |
| DE2025810B2 DE2025810B2 (de) | 1980-06-26 |
| DE2025810C3 true DE2025810C3 (de) | 1981-03-19 |
Family
ID=12579713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2025810A Expired DE2025810C3 (de) | 1969-05-26 | 1970-05-26 | Verfahren zur Isolierung doppelstrangiger Ribonucleinsäure und diese Verbindung enthaltendes Arzneipräparat |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US3907778A (OSRAM) |
| BE (1) | BE750918A (OSRAM) |
| CA (1) | CA932284A (OSRAM) |
| DE (1) | DE2025810C3 (OSRAM) |
| FR (1) | FR2051558B1 (OSRAM) |
| GB (1) | GB1303506A (OSRAM) |
| NL (1) | NL148241B (OSRAM) |
| SE (1) | SE376170B (OSRAM) |
| ZA (1) | ZA703501B (OSRAM) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3157637A (en) * | 1963-05-21 | 1964-11-17 | Joseph X Khym | Method of separating nucleotides |
| US3444041A (en) * | 1965-09-29 | 1969-05-13 | Univ Illinois | In vitro synthesis of ribonucleic acids and enzyme therefor |
| US3389133A (en) * | 1966-08-10 | 1968-06-18 | Schwarz Biores Inc | Process for isolating and purifying soluble ribonucleic acid |
-
1970
- 1970-05-15 US US037698A patent/US3907778A/en not_active Expired - Lifetime
- 1970-05-22 GB GB2492270A patent/GB1303506A/en not_active Expired
- 1970-05-25 ZA ZA703501A patent/ZA703501B/xx unknown
- 1970-05-25 SE SE7007144A patent/SE376170B/xx unknown
- 1970-05-25 FR FR707018968A patent/FR2051558B1/fr not_active Expired
- 1970-05-25 NL NL707007521A patent/NL148241B/xx not_active IP Right Cessation
- 1970-05-25 BE BE750918D patent/BE750918A/xx not_active IP Right Cessation
- 1970-05-25 CA CA083655A patent/CA932284A/en not_active Expired
- 1970-05-26 DE DE2025810A patent/DE2025810C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2051558A1 (OSRAM) | 1971-04-09 |
| DE2025810B2 (de) | 1980-06-26 |
| DE2025810A1 (de) | 1970-12-17 |
| NL7007521A (OSRAM) | 1970-11-30 |
| ZA703501B (en) | 1971-01-27 |
| GB1303506A (OSRAM) | 1973-01-17 |
| FR2051558B1 (OSRAM) | 1974-06-14 |
| CA932284A (en) | 1973-08-21 |
| NL148241B (nl) | 1976-01-15 |
| US3907778A (en) | 1975-09-23 |
| BE750918A (fr) | 1970-11-03 |
| SE376170B (OSRAM) | 1975-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68908971T2 (de) | Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen. | |
| DE2051745A1 (de) | Von Nucleinsäuren stammende Arznei mittel und Verfahren zu ihrer Herstellung | |
| CH629668A5 (de) | Verfahren zum reinigen von hepatitis-b-antigen. | |
| DE3019847C2 (de) | Verfahren zur Herstellung von Humaninterferon | |
| DE69634530T2 (de) | Antivirales mittel und verfahren zu dessen herstellung | |
| DE1965431C3 (de) | Inosin-Komplexverbindungen und Verfahren zu ihrer Herstellung | |
| DE1695976B2 (de) | 4-Hydroxy-l- ß -D-ribofuranosyl- tetrahydro-2 (lH)-pyrimidinon, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE1695278A1 (de) | Neue chemische Verbindungen und ihre Darstellungen und Behandlungen | |
| DE2823750C3 (de) | Verfahren zur Gewinnung mindestens eines Hydrolyseprodukts eines Endotoxins von Bordetella Pertussis | |
| DE2734150A1 (de) | Verfahren zur gewinnung von human- lysozym | |
| DE68903065T2 (de) | Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien. | |
| DD261094A5 (de) | Verwendung der verbindung 1-beta-d-ribofuranosyl-1,2,4,-triazol-3-carbonsaeureamid zur herstellung einer pharmazeutischen zusammensetzung | |
| DE2048848A1 (de) | Verfahren zur Herstellung eines Korn plexes aus RNS und Polysacchand, Verfahren zur Gewinnung der Polysacchand Komponente und ihre Verwendung zur Herstellung von Arzneimitteln | |
| DE2124123A1 (de) | Polynucleotid und Verfahren zu deren Herstellung | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| DE2655690A1 (de) | Arzneimittelzubereitungen | |
| DE2064296C2 (de) | Verfahren zur Herstellung eines injizierbaren Mittels gegen Viren der Mäuseleukämien | |
| DE2025810B2 (de) | Verfahren zur Isolierung doppelstrangiger Ribonucleinsäure und diese Verbindung enthaltendes Arzneipräparat | |
| DE1617659A1 (de) | Polynucleotide,welche als die Interferonerzeugung in lebenden tierischen Zellen induzierende Verbindungen wirksam sind | |
| CH646875A5 (de) | Verfahren zur gewinnung eines interferons und interferon hergestellt nach diesem verfahren. | |
| DE1642612A1 (de) | Die Verwendung von Erythrozyten zur Gewinnung bzw.Isolierung eines Plasminogen-Aktivators | |
| DE2305553A1 (de) | Arzneimittel zur behandlung von virusinfektionen | |
| DE4206574C1 (en) | Fractionation method of parts of hepatitis C virus - by concn. of complexes of virus parts and lipoprotein(s) having low densities useful in hepatitis C virus detection and distinction of variants | |
| DE2225548C3 (de) | Intravenös verträglicher Impfstoff gegen Staupe- und Hepatite contagiosa canis | |
| LU81348A1 (de) | Antiviral wirksame t-rna-praeparate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |